



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville MD 20857

APR 13 1993

Re: PAXIL®
Docket No. 93E-0146

Charles E. Van Horn
Patent Policy and Projects Administrator
Office of the Assistant Commissioner for Patents
U.S. Patent and Trademark Office
Crystal Park Building 2, Suite 919
Washington, D.C. 20231

RECEIVED
93 APR 15 AM 11:34
FEDERAL BUREAU OF INVESTIGATION
COMMUNICATIONS SECTION

Dear Mr. Van Horn:

This is in regard to the application for patent term extension for U.S. Patent No. 4,721,723 filed by Beecham Group p.l.c. under 35 U.S.C. § 156. The human drug product claimed by the patent is PAXIL® (paroxetine hydrochloride), which was assigned New Drug Application (NDA) No. 20-031.

A review of the Food and Drug Administration's official records indicates that this product was subject to a regulatory review period before its commercial marketing or use, as required under 35 U.S.C. § 156(a)(4). Our records also indicate that it represents the first permitted commercial marketing or use of the product.

The NDA was approved on December 29, 1992, which makes the submission of the patent term extension application on February 22, 1993, timely within the meaning of 35 U.S.C. § 156(d)(1).

Should you conclude that the subject patent is eligible for patent term extension, please advise us accordingly. As required by 35 U.S.C. § 156(d)(2)(A), we will then determine the applicable regulatory review period, publish the determination in the Federal Register, and notify you of our determination.

Please let me know if we can be of further assistance.

Sincerely,

Ronald L. Wilson, Director
Health Assessment Policy Staff
Office of Health Affairs

cc: Edward T. Lentz
Corporate Patents U.S.- UW2220
SmithKline Beecham Corporation
P.O.Box 1539
King of Prussia, PA 19406-0939